Suzhou Yabao pharmaceutical R & D Co., Ltd. (hereinafter referred to as "Suzhou Yabao") announced that a few months ago it would transfer the project of monoclonal antibody against human preprotein invertase subtilis lysozyme 9 for injection (PCSK9 monoclonal antibody) to Zhongshan kangfang biomedical Co., Ltd. (hereinafter referred to as "Zhongshan kangfang"). The project was jointly developed by Suzhou Yabao and Zhongshan kangfang. When the preclinical development was officially launched, Zhongshan kangfang bought back all rights and interests.
Suzhou Yabao, which is well-known in the industry for the introduction and development of international projects, the external transfer of its projects is also one of the basic contents of its business model. This is a time for two emerging biomedical enterprises focusing on "innovation and cooperation" to join hands and continue to lead the cooperation of similar projects. We hope to establish more extensive export-oriented cooperation and jointly accelerate the process of new drug research and development.
About PCSK9 McAb
PCSK9 monoclonal antibody is a new antibody against Subtilisin Protease with pre protein invertase activity, which is used to treat hyperlipidemia. PCSK9 mAb can be used in patients who cannot achieve the expected effect with statins or cannot tolerate statins. The target drugs have not been listed in China, and the project cooperated by Yabao and Zhongshan kangfang is currently in progress in China.
About Zhongshan kangfang
Zhongshan kangfang biomedical Co., Ltd. is an innovative biopharmaceutical company headquartered in the health industry base of Torch Development Zone, Zhongshan City, Guangdong Province. The overseas returnee entrepreneurship team led by experts of the "thousand talents plan" was established in March 2012. We are committed to discovering and developing innovative antibody new drugs with independent intellectual property rights to meet the needs of the pharmaceutical market at home and abroad. At present, the company has built an international level biopharmaceutical whole process R & D and industrialization platform; It has established a rich product line for tumors, autoimmune diseases, inflammation and cardiovascular diseases. The company's platform scale, software and hardware facilities, number of new drug product lines and R & D team are at the same industry level in China.
Kangfang biology has established cooperative relations with many international and domestic listed pharmaceutical enterprises to jointly develop innovative antibody new drugs. It is a pioneer in developing antibody new drugs in the form of strategic cooperation in China.
For more information, please go to http://www.akesobio.com/
About Suzhou Yabao
Suzhou Yabao is a biological company committed to developing revolutionary and innovative drugs with international prospects through international cooperation. In April 2014, Dr. Wang Peng, a distinguished expert of the "thousand talents plan", was founded and served as president. He is a holding subsidiary of Yabao Pharmaceutical Group, a well-known domestic listed pharmaceutical company.
In just two and a half years, Suzhou Yabao has established cooperative relations with global famous enterprises and colleges such as Lilly pharmaceutical, University of South Australia, University of Western Ontario, science and Technology Department of British Medical College and so on. And has established a domestic innovative drug development team.
At present, eight class 1 innovative drug projects are under development, of which one has completed international clinical phase 1 (and has been approved to carry out clinical research in China), and the other has also carried out international clinical phase 1 and has been applied for clinical trials in China.
For more information, please go to http://www.suzhouyabao.com/
September 2016
请将简历发送至：